{
    "root": "7ec5f8ea-6c1f-41c7-929a-7e8acc7ff63a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clozapine",
    "value": "20240906",
    "ingredients": [
        {
            "name": "CLOZAPINE",
            "code": "J60AR2IKIC"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PEPPERMINT",
            "code": "V95R5KMY2B"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "XYLITOL",
            "code": "VCQ006KQ1E"
        }
    ],
    "indications": "Clozapine orally disintegrating tablets are an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( 1.1 , 14.1 ) Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( 1.2 , 14.2 )",
    "contraindications": "Starting Dose: 12.5 mg once daily or twice daily. ( 2.3 ) Use cautious titration and divided dosage schedule. ( 2.3 , 5.3 ) Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated. ( 2.3 ) Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks. ( 2.3 ) Subsequent increases: increase in increments of 100 mg or less, once or twice weekly. ( 2.3 ) Maximum daily dose: 900 mg ( 2.3 ) Tablets rapidly disintegrate after placement in the mouth and may be chewed if desired. No water is needed ( 2.3 ).",
    "warningsAndPrecautions": "12.5 mg \n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I3 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5416-01).\n                           \n                           25 mg \n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I7 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5417-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5417-84). \n                        \n                           100 mg \n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I2 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5419-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5419-84).\n                        \n                           150 mg\n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I1 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5376-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5376-84).\n                        \n                           200 mg\n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with L1 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5377-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5377-84).",
    "adverseReactions": "Clozapine orally disintegrating tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine orally disintegrating tabletsÂ [see Adverse Reactions (6.2)]."
}